What it is
Kisspeptin is a neuropeptide — a small chain of amino acids that acts as a signalling molecule in the brain. It is made by nerve cells in the hypothalamus, a control centre deep in the brain that governs the release of several important hormones. The full-length form is kisspeptin-54. Kisspeptin-10 is the active 10 amino acid piece cut from one end of it, and it works just as well at its target as the larger molecule.
The hormones it controls are GnRH (gonadotropin-releasing hormone), LH (luteinising hormone), and FSH (follicle-stimulating hormone). Together they run the reproductive system in men and women. The hypothalamus releases GnRH, GnRH tells the pituitary gland to release LH and FSH, LH tells the testicles to make testosterone, and FSH tells them to make sperm. Kisspeptin sits above all of this. It is the signal that tells the GnRH cells to fire — the master switch at the very top of the chain.
That position matters. Enclomiphene works by blocking the brain's view of oestrogen, HCG skips the brain and talks straight to the testicles, and testosterone therapy switches the whole chain off. Kisspeptin presses the accelerator on GnRH while leaving every natural safety brake in place. That is why it is discussed as a natural alternative to HCG.
Beyond reproduction, it plays a role in the release of aldosterone (the hormone that regulates water and salt balance), in suppressing tumours, and in kidney function. It was originally named Metastin, a name that reflects its ability to stop cancer spreading.
It is not approved by the FDA for human use and is classed as a research peptide. It arrives as a dry powder in a sealed glass vial. You add bacteriostatic water (sterile water with a preservative that lets it keep for weeks), then inject it just under the skin — a subcutaneous injection.
Kisspeptin is a hypothalamic neuropeptide, the product of the KISS1 gene, acting at the G-protein coupled receptor KISS1R (formerly GPR54). Kisspeptin-54 is the full-length endogenous form; kisspeptin-10 is the biologically active C-terminal decapeptide fragment, which retains full receptor-binding activity and is the form supplied for research use.
It is the proximal upstream regulator of the hypothalamic-pituitary-gonadal axis. KISS1R activation on GnRH neurons drives pulsatile GnRH release, which stimulates pituitary LH and FSH secretion and downstream sex steroid production — testosterone, oestrogen, and progesterone — as well as FSH-driven spermatogenesis. Without kisspeptin signalling GnRH neurons do not activate and the axis is silent. It also increases HCG-stimulated progesterone secretion in luteal cells.
Outside the reproductive axis it contributes to aldosterone secretion, tumour suppression, and renal function. Its original name, Metastin, reflects the metastasis-suppressing activity that led to its discovery.
The clinically interesting property is positional, and the analogy is to GHRH analogues such as CJC-1295 or tesamorelin on the somatotropic axis. Enclomiphene removes the oestrogen brake at the hypothalamus and pituitary; HCG bypasses the brain as an LH-receptor agonist; TRT suppresses the axis through negative feedback. Kisspeptin instead recruits the intact axis from the top, with oestradiol feedback fully functional — the basis for framing it as a natural alternative to HCG for maintaining fertility and hormonal balance.
Desensitisation occurs with continuous exposure via beta-arrestin-mediated KISS1R internalisation, so the axis's pulsatile character constrains dosing frequency. Kisspeptin-10 is not FDA approved for human use and is classified as a research peptide.
How it works
Kisspeptin locks onto a receptor called KISS1R (a receptor is a docking point on a cell that triggers an action when the right molecule lands on it). These receptors sit on the GnRH cells in the hypothalamus. Think of the GnRH cells as workers waiting for a manager. Kisspeptin is the manager. When it arrives, the workers start, and GnRH is released in pulses.
That GnRH pulse travels to the pituitary gland, which releases LH and FSH. LH travels to the Leydig cells in the testicles and tells them to make testosterone. FSH goes to the Sertoli cells and tells them to make sperm. As testosterone rises, some of it converts to oestradiol, and that oestradiol feeds back to the brain and tells it to ease off. This is the brake, and kisspeptin leaves it fully working. That is why testosterone cannot be pushed to the extreme levels possible with injected testosterone.
There is one important catch. If the receptor is stimulated all the time it gets pulled inside the cell and stops responding — desensitisation. In women with hypothalamic amenorrhea, twice-daily kisspeptin-54 gave a strong LH rise on day 1 but the response was much weaker by 2 weeks; when dosing was cut to twice weekly, the effect held over 8 weeks with only a modest fall. This is why the protocol uses every-other-day or twice-weekly dosing rather than daily.
Kisspeptin-10 is cleared from the blood quickly. After an injection under the skin, LH peaks at about 30 to 40 minutes and drifts back towards normal by 180 minutes (3 hours). Earlier guidance on this page recorded LH and testosterone peaking at 45 to 60 minutes with effects lasting up to 24 hours; current figures are the shorter ones above.
Kisspeptin-10 binds KISS1R (GPR54), a Gq-coupled GPCR expressed on hypothalamic GnRH neurons, triggering pulsatile GnRH secretion. GnRH acts at the anterior pituitary to release LH and FSH. LH stimulates Leydig cell testosterone synthesis; FSH acts on Sertoli cells to support spermatogenesis. Testosterone and its aromatised metabolite oestradiol feed back on the hypothalamus and pituitary, modulating the next GnRH pulse.
The defining feature is that negative feedback remains intact throughout. Rising oestradiol attenuates subsequent GnRH output, so testosterone cannot be driven into supraphysiological ranges the way exogenous testosterone allows, and there is no intratesticular overshoot of the kind HCG can produce. The principle parallels GHRH analogues, where somatostatin tone still governs GH output regardless of GHRH dose.
Desensitisation is the mechanistic constraint. Continuous KISS1R stimulation produces beta-arrestin-mediated receptor internalisation and tachyphylaxis. In women with hypothalamic amenorrhea, twice-daily kisspeptin-54 produced robust LH increases on day 1 but a markedly reduced response by 2 weeks; reducing to twice-weekly dosing maintained stimulation over 8 weeks with only modest decline. Every-other-day and twice-weekly protocols exist to stay on the right side of this.
Pharmacokinetics: kisspeptin-10 has a short half-life and is rapidly cleared. After subcutaneous injection, peak LH occurs at approximately 30 to 40 minutes, returning towards baseline by 180 minutes. In IV bolus work, 1 mcg/kg raised LH from 4.1 IU/L to 12.4 IU/L within 30 minutes and increased both LH pulse frequency and pulse size. Earlier guidance on this page recorded a 45-60 minute LH and testosterone peak and effects persisting up to 24 hours; the shorter kinetic figures above are the current ones for kisspeptin-10.
What it does
Hormones and reproduction: it stimulates GnRH, which stimulates LH, FSH, and the sex steroid hormones. That raises testosterone, oestrogen, and progesterone without switching off your own production — so when you stop, your natural output carries on at whatever level it was before, with no recovery period. Because it raises both LH and FSH, it supports testosterone and sperm production at the same time, which is an advantage over HCG. It regulates reproductive hormones, enhances fertility, treats fertility disorders, plays a role in the onset of puberty, and increases progesterone production in corpus luteum cells when HCG is present.
Sexual function: it acts directly on the brain's sexual processing network. In a 2023 randomised trial of men with low sexual desire, it increased penile response to sexual stimuli by up to 56% compared with placebo and raised feelings of happiness about sex. It is also a possible remedy for erectile dysfunction.
Metabolism: it aids metabolic function, promotes weight loss, and boosts insulin secretion. In men with type 2 diabetes and mildly low testosterone it raised LH pulses and testosterone.
Liver: it increases antioxidants in the liver, and for early-stage non-alcoholic fatty liver disease it both reduces fat already deposited and prevents new fat accumulating.
Other: it boosts immunity, improves thinking, prevents wrinkles and signs of ageing, temporarily increases oxytocin (the bonding hormone), lowers the risk of heart disease, and is a potential treatment for polycystic ovary syndrome.
HPG axis: KISS1R agonism drives pulsatile GnRH release, LH and FSH secretion, and downstream sex steroid production. Testosterone rises via LH-mediated Leydig cell stimulation; oestrogen and progesterone also increase; FSH-driven spermatogenesis is supported concurrently, a point of advantage over HCG, which primarily stimulates LH with inconsistent FSH effects. Increases HCG-stimulated progesterone secretion in luteal cells. Regulates reproductive hormone release, enhances fertility, treats fertility disorders, and mediates pubertal onset. Because the axis is never suppressed, cessation returns output to baseline with no post-cycle recovery requirement. In a 22.5-hour infusion in healthy men, LH rose from 5.4 to 20.8 IU/L and testosterone from 16.6 to 24.0 nmol/L (roughly a 45% increase). In men with type 2 diabetes and mild biochemical hypogonadism it increased LH pulse frequency and secretion with associated testosterone rises.
Sexual function: independent of gonadal output, kisspeptin modulates limbic sexual processing. In a 2023 JAMA Network Open randomised crossover trial of 32 men with HSDD it increased penile tumescence by up to 56% versus placebo and raised behavioural measures of sexual desire. Possible role in erectile dysfunction.
Metabolic: aids metabolic function and promotes weight loss; increases insulin secretion.
Hepatic: increases hepatic antioxidants. In early-stage NAFLD it reduces existing hepatic fat deposition and prevents initial accumulation.
Other: immune enhancement, improved cognitive function, anti-wrinkle and anti-ageing effect, transient oxytocin elevation, reduced cardiovascular risk, and potential application in polycystic ovarian syndrome.
In practice the response is moderate and physiological rather than the abrupt rise seen with HCG; users expecting HCG-level changes report disappointment.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Increases testosterone by stimulating luteinising hormone, which drives the Leydig cells in the testicles to make testosterone.Human trials
- Raises testosterone without shutting down your own hormone system, so nothing needs recovering when you stop.Anecdotal
- Supports both testosterone and sperm production because it raises LH and FSH together — an advantage over HCG for fertility preservation.Anecdotal
- Increased penile response to sexual stimuli by up to 56% versus placebo in men with low sexual desire in a 2023 trial, and improved how they felt about sex.Human trials
- Boosts immunity.Anecdotal
- Regulates the release of reproductive hormones.Human trials
- Enhances fertility and treats fertility disorders.Human trials
- Aids metabolic function and promotes weight loss.Animal or lab only
- Prevents wrinkles and signs of ageing.Anecdotal
- Boosts thinking and mental function.Animal or lab only
- Increases antioxidants in the liver.Animal or lab only
- Temporarily increases oxytocin, the bonding hormone.Animal or lab only
- Boosts insulin secretion.Human trials
- A possible remedy for erectile dysfunction.Limited human data
- Responds to sexual stimuli and affects how frequently hormonal pulses occur.Human trials
- Lowers the risk of heart disease.Anecdotal
- Plays a role in the onset of puberty.Limited human data
- A potential treatment for polycystic ovary syndrome.Limited human data
- For early-stage non-alcoholic fatty liver disease: reduces fat already in the liver and prevents more accumulating.Animal or lab only
- May work as a natural alternative to HCG for maintaining fertility and hormonal balance during testosterone therapy.Anecdotal
- Raises testosterone via LH-mediated Leydig cell stimulation.Human trials
- Testosterone optimisation without HPG axis suppression; oestradiol feedback stays intact, so output is self-limiting and reversible on cessation with no post-cycle recovery period.Anecdotal
- Fertility preservation: concurrent LH and FSH stimulation supports both steroidogenesis and spermatogenesis, unlike HCG's primarily LH-mediated effect.Anecdotal
- Central sexual desire enhancement: up to 56% increase in penile tumescence versus placebo and modulation of sexual brain processing in a 2023 JAMA Network Open RCT in men with HSDD.Human trials
- Immune enhancement.Anecdotal
- Regulates reproductive hormone release.Human trials
- Enhances fertility; treats fertility disorders.Human trials
- Aids metabolic function and promotes weight loss.Animal or lab only
- Anti-wrinkle and anti-ageing effect.Anecdotal
- Improved cognitive function.Animal or lab only
- Increases hepatic antioxidants.Animal or lab only
- Transient oxytocin elevation.Animal or lab only
- Increases insulin secretion.Human trials
- Possible application in erectile dysfunction.Limited human data
- Responds to sexual stimuli; modulates hormonal pulse frequency.Human trials
- Reduced cardiovascular risk.Anecdotal
- Mediates pubertal onset.Limited human data
- Potential treatment for polycystic ovarian syndrome.Limited human data
- Early-stage NAFLD: reduces existing hepatic fat and prevents initial accumulation.Animal or lab only
- Positioned upstream of GnRH, so it restores the HPG axis rather than bypassing it — the case for it as an alternative to HCG during testosterone therapy.Anecdotal
- Increases HCG-stimulated progesterone secretion in luteal cells.Animal or lab only
What to expect
The hormone response is fast. LH peaks about 30 to 40 minutes after an injection under the skin. In an infusion study, testosterone rose from an average of 16.6 nmol/L to 24.0 nmol/L (roughly a 45% increase) over 22.5 hours.
With the every-other-day protocol, most people should see changes on blood tests within 2 to 4 weeks. Run baseline labs before you start and recheck at 4 weeks, looking at LH, total and free testosterone, oestradiol, and FSH.
What users report: some notice better energy, sex drive, and mood within the first 2 to 3 weeks. One user reported a 40% rise in total testosterone after a month on 100 mcg daily, but was taking other compounds too, so that cannot be pinned on kisspeptin. Users who have tried enclomiphene sometimes prefer kisspeptin because it does not cause the flat mood some people get from blocking oestrogen.
Manage your expectations. The effect is generally described as more subtle than HCG or enclomiphene. People hoping for a dramatic HCG-style jump often report disappointment, and some see no clear change on bloodwork. Those who understand it produces a moderate, natural-feeling response tend to be satisfied. Every-other-day injections and the cost relative to the effect are common complaints.
Side effects are usually minimal to none at standard doses. Users mention injection site irritation, mild flushing, and mild headache most often, with temporary warmth and lightheadedness less often.
Onset is rapid: peak LH at approximately 30 to 40 minutes post-subcutaneous injection, returning towards baseline by 180 minutes. In the 22.5-hour infusion study, testosterone rose from a mean of 16.6 nmol/L to 24.0 nmol/L (roughly 45%).
On every-other-day dosing, biochemical change is expected within 2 to 4 weeks. Baseline labs before starting and a recheck at 4 weeks: LH to confirm GnRH stimulation, total and free testosterone for downstream response, oestradiol to track aromatisation, and FSH to confirm the gonadotropin response.
In practice the evidence base is thinner than for enclomiphene or HCG and user reports are fewer. Some users report improved energy, libido, and mood within 2 to 3 weeks. One user reported a 40% increase in total testosterone after one month on 100 mcg daily while taking other compounds concurrently, so attribution is not possible. Users who have used both often prefer kisspeptin over enclomiphene because it does not antagonise oestrogen receptors and therefore avoids SERM-associated emotional flattening; a subset describe it as feeling more physiological.
The most common negative report is subtlety relative to expectation. Users anticipating HCG-level testosterone increases report disappointment, and some see no discernible change on bloodwork. Every-other-day injection frequency and cost relative to perceived effect are recurring complaints.
Tolerability is very mild compared with enclomiphene, HCG, or TRT. No adverse events were reported in the foundational human studies or the 2023 JAMA Network Open trial. User-reported effects: injection site irritation, mild flushing, and mild headache (common); temporary warmth and lightheadedness (less common).
Reconstitution and dosing
Kisspeptin comes as a dry powder in a 5 mg vial. Mix it with 2 mL of bacteriostatic water. Add the water slowly down the inside wall of the vial and swirl gently — do not shake. That gives 250 mcg per 10 units on an insulin syringe, so 100 mcg is 4 units, 150 mcg is 6 units, and 200 mcg is 8 units.
Inject just under the skin, morning or evening. No fasting is needed. Earlier guidance recommended fasted dosing, saying it raised the LH response five to six times; current guidance is that fasting is not required.
The standard dose is 100 to 200 mcg every other day. Start at the low end and go up only if you need to. A rough guide by body weight: under 150 lbs, 100 mcg; 150 to 200 lbs, 100 to 150 mcg; over 200 lbs, 150 to 200 mcg — all every other day.
Run a cycle for 4 to 8 weeks, then take a break. Some practitioners suggest 4 to 6 week cycles; in practice most users run 4 to 6 weeks with lab checks. The best cycling pattern has not been established by research.
Do not dose daily for long periods. Constant stimulation makes the receptor stop responding. Every-other-day or twice-weekly dosing is what prevents this. A smaller group of users follows twice-weekly protocols.
Get blood tests before you start and again 4 weeks in: LH, total and free testosterone, oestradiol, and FSH.
If you are on testosterone therapy, kisspeptin is unlikely to work, because your GnRH cells are already switched off by the testosterone.
These doses come from practice, not from published dose-finding studies. Published trials used intravenous kisspeptin-10 at 0.3 to 4 mcg/kg, and 1 mcg/kg as a single bolus gave the biggest LH rise in healthy men.
Reconstitute the 5 mg vial with 2 mL bacteriostatic water, giving 250 mcg per 10 units on an insulin syringe: 100 mcg = 4 units, 150 mcg = 6 units, 200 mcg = 8 units. Add diluent down the vial wall and swirl; do not shake.
Subcutaneous administration, morning or evening, no fasting required. Earlier guidance recommended fasted dosing on the basis of a 5-6× greater LH response; current guidance explicitly drops the fasting requirement, which removes any timing conflict with GH secretagogues, which do need fasting.
Standard protocol: 100 to 200 mcg every other day, 4 to 8 weeks per cycle, labs at baseline and 4 weeks (LH, total and free testosterone, oestradiol, FSH). Body-weight tiers: under 150 lbs, 100 mcg; 150 to 200 lbs, 100 to 150 mcg; over 200 lbs, 150 to 200 mcg, all every other day. In practice most users run 100 to 200 mcg every other day for 4 to 6 weeks; some use 100 mcg daily; a smaller group uses twice-weekly dosing. Optimal cycling is not established by published research.
Frequency is the governing variable. Continuous exposure produces beta-arrestin-mediated KISS1R internalisation and tachyphylaxis — twice-daily kisspeptin-54 lost most of its LH response by 2 weeks, while twice-weekly dosing held over 8 weeks. Every-other-day or twice-weekly schedules are the design response; sustained daily dosing is the pattern to avoid.
Concurrent TRT makes the protocol pharmacologically redundant: exogenous testosterone and oestradiol silence GnRH neurons through negative feedback, leaving nothing for KISS1R agonism to stimulate.
The practical protocol is not derived from dose-finding studies. Published work used intravenous kisspeptin-10 at 0.3 to 4 mcg/kg by bolus or continuous infusion, with maximal LH stimulation in healthy men at 1 mcg/kg as a single IV bolus. No published dose-finding data exist for subcutaneous every-other-day use.
The previous site protocol (1.5 mL reconstitution, 200 to 500 mcg every other day, 4 weeks on and 4 off) has been superseded by the figures above.
Standard, 5 mg vial
Mix with 2 mL (200 units) of bacteriostatic water.
2.5 mg/mL · 25 mcg per unit
Cycle: 4 to 8 weeks per cycle; labs at baseline and 4 weeks · Frequency: Every other day; morning or evening; no fasting required
| When | Dose | Draw | How often |
|---|---|---|---|
| Starting (4 units) | 100 mcg | 4 units | 1×, every other day |
| Full (8 units) | 200 mcg | 8 units | 1×, every other day |
Alternative protocols
Alternative protocols reflect older community practice and are kept for reference.
Alternative, 5 mg vial — standard protocol
Mix with 1.5 mL (150 units) of bacteriostatic water.
3.33 mg/mL · 33.33 mcg per unit
Cycle: 4 weeks, then a 4-week washout · Frequency: Every other day; fasted; any time of day. 2×/week is separately given as the optimal frequency to avoid desensitisation
| When | Dose | Draw | How often |
|---|---|---|---|
| Initial dose (6 units) — start here | 200 mcg | 6 units | 1×/day, every other day |
| Step 2 (9 units) | 300 mcg | 9 units | 1×/day, every other day |
| Step 3 (12 units) | 400 mcg | 12 units | 1×/day, every other day |
| Step 4, top of the scale (15 units) | 500 mcg | 15 units | 1×/day, every other day |
5 mg in 2 mL is 2.5 mg/mL, or 25 mcg per unit. Draw 4 units (0.04 mL) for 100 mcg.
Who should avoid it
- Anyone with a known allergy to kisspeptin or anything else in the vial should not use it.
- Anyone with primary hypogonadism, meaning the testicles themselves have failed, should not use it. Kisspeptin works by sending a signal from the brain downwards; if the problem is in the testicles, the signal has nowhere to go and it cannot help.
- Anyone with an active pituitary tumour, or any condition affecting how the pituitary gland works, should not use it.
- Anyone with a hormone-sensitive cancer should not use it. Kisspeptin raises testosterone, oestrogen, and progesterone, all of which can feed these cancers.
- Anyone pregnant or breastfeeding should not use it without a doctor's guidance. There is no safety data at all, and because the compound acts on the reproductive hormone system and raises oestrogen and progesterone, this is not a risk to take lightly.
- Anyone being treated for any other hormone-sensitive condition should speak to a doctor before considering it.
- Anyone with a condition affecting the hypothalamus or pituitary gland should use caution and get medical input first.
- Anyone already using other treatments that act on the reproductive hormone system, such as enclomiphene, tamoxifen, HCG, or HMG, should discuss the combination with a physician. They all push on the same chain and no proper interaction studies exist.
- Anyone on testosterone replacement therapy (TRT) should know that kisspeptin is unlikely to work at all, because TRT switches off the very brain signals kisspeptin is trying to stimulate.
- A practical caution rather than a contraindication: using it too often causes desensitisation, meaning the receptors stop responding and it stops working. Start at the lowest dose and increase only as tolerated and as needed.
- Known hypersensitivity to kisspeptin or any excipient.
- Primary hypogonadism (testicular failure). The lesion is downstream of GnRH and LH; upstream KISS1R agonism cannot restore Leydig or Sertoli output when the gonad itself is the problem.
- Active pituitary tumours or any condition compromising pituitary function. The pituitary gonadotroph response is the necessary intermediate step; without it, GnRH stimulation is inert.
- Hormone-sensitive cancers. Kisspeptin raises testosterone, oestradiol, and progesterone via the intact HPG axis, and there is no mechanism to prevent that rise in a patient with a steroid-dependent tumour.
- Pregnancy and lactation warrant physician input at minimum. No safety data exist, and the compound directly modulates an axis whose behaviour in pregnancy is already dramatically altered. This is a formal caution.
- Hormone-sensitive disease of any kind requires physician input before use, given the sex steroid elevation.
- Any hypothalamic or pituitary disorder, including those short of a tumour, is a caution.
- Concurrent HPG-axis interventions are a caution. Theoretical interactions exist with SERMs (enclomiphene, tamoxifen) and gonadotropins (HCG, HMG) since all act on the same axis; no well-established drug interactions have been documented because human research remains limited.
- Exogenous testosterone (TRT) is a pharmacological contradiction rather than a contraindication: negative feedback from exogenous androgen and its oestradiol metabolite silences GnRH neurons, so there is little for KISS1R agonism to act on.
- Protocol-level caution: continuous stimulation produces beta-arrestin-mediated KISS1R internalisation and tachyphylaxis. Start at the lowest dose and titrate only as tolerated and necessary.
- Regulatory note: not FDA approved for human use and classified as a research peptide.
Side effects
- Published studies report a good safety record. No adverse events were reported in the foundational human studies or in the 2023 JAMA Network Open trial, and none were reported with intranasal kisspeptin-54 either.
- Users most commonly report irritation at the injection site, mild flushing, and mild headache.
- Less commonly users report a temporary feeling of warmth and light-headedness.
- Other reported effects include diarrhoea, sweating, hot flushes, dizziness, a shortened menstrual cycle, and changes in metabolism caused by eating less. All of these are described as very uncommon.
- The main concern is not an acute side effect but desensitisation: dosing too often makes the receptors stop responding, so the compound loses its effect. In the 2009 study of women with hypothalamic amenorrhoea, twice-daily dosing produced strong luteinising hormone rises on day 1 but a markedly reduced response by 2 weeks, whereas twice-weekly dosing held up over 8 weeks with only modest decline.
- One animal study found that chronic subcutaneous kisspeptin-54 caused testicular degeneration in rats. That was continuous high-dose exposure, not comparable to the every-other-day or twice-weekly protocols used in practice, but it is another reason not to dose continuously.
- Most users report minimal to no side effects at standard doses, and the profile is generally described as very mild compared with enclomiphene, HCG, or TRT.
- Published clinical studies show a favourable safety profile. No adverse events were reported in the foundational human studies (Dhillo et al., 2005; George et al., 2011) or in the 2023 JAMA Network Open trial (Comninos et al., 2023). The intranasal kisspeptin-54 study (Sonmez et al., 2025) likewise reported no side effects or adverse events.
- Commonly reported by users: injection site irritation, mild flushing, mild headache.
- Less commonly reported: transient warmth, light-headedness.
- Also reported and characterised as very uncommon: diarrhoea, sweating, hot flushes, dizziness, shortened menstrual cycle, and altered metabolism secondary to decreased food intake.
- The principal pharmacological concern is tachyphylaxis rather than acute toxicity. Continuous KISS1R stimulation drives beta-arrestin-mediated receptor internalisation. Jayasena et al. (2009) showed twice-daily kisspeptin-54 in women with hypothalamic amenorrhoea produced robust LH rises on day 1 but a markedly reduced response by 2 weeks, while twice-weekly dosing maintained stimulation over 8 weeks with only modest decline.
- Thompson et al. (2006) reported testicular degeneration in adult male rats with chronic subcutaneous kisspeptin-54. The exposure was continuous and high-dose and is not comparable to intermittent human protocols, but it reinforces the frequency constraint.
- Monitor oestradiol as testosterone rises; aromatisation is the expected consequence of LH-driven testosterone production and is a lab parameter for that reason.
- Most users report minimal to no side effects at standard doses; the profile is described as very mild relative to enclomiphene, HCG, or TRT.
What the evidence shows
The human research on kisspeptin comes mostly from academic studies rather than drug-company trials, so it is smaller in scale than the research behind older fertility drugs.
The key early work was published between 2005 and 2011. In healthy men, kisspeptin-10 given into a vein at 1 mcg/kg produced a rapid, dose-dependent rise in luteinising hormone, from 4.1 IU/L to 12.4 IU/L within 30 minutes. In a 22.5-hour infusion, luteinising hormone rose from 5.4 to 20.8 IU/L and testosterone rose from 16.6 to 24.0 nmol/L, roughly a 45% increase. Hormone pulses also became more frequent and larger.
In men with type 2 diabetes and mildly low testosterone, kisspeptin-10 increased luteinising hormone pulses and secretion, with a matching rise in testosterone. The authors saw a potential new role for kisspeptin in boosting the body's own testosterone in this group.
The most striking recent study is the 2023 trial in JAMA Network Open (Comninos et al., 2023). It enrolled 32 men with hypoactive sexual desire disorder in a randomised, double-blind, crossover design. Kisspeptin changed brain activity in the regions that process sexual stimuli, increased penile tumescence by up to 56% compared with placebo, and improved measures of sexual desire and happiness about sex.
On dosing frequency, a 2009 study in women showed that twice-daily kisspeptin-54 stopped working well by 2 weeks, while twice-weekly dosing kept working over 8 weeks.
A 2024 review in Endocrine Reviews described kisspeptin as having emerging therapeutic potential for reproductive disorders but noted development is still early. A 2025 study showed intranasal kisspeptin-54 rapidly stimulated gonadotropin release in healthy men and women without adverse events.
What is missing: there are no large trials of subcutaneous kisspeptin-10 taken every other day for testosterone in otherwise healthy men, and no published dose-finding work for that protocol. The practical doses used are based on clinical practice, not trials. If you use it, run baseline bloods and recheck at 4 weeks so you know whether it is doing anything.
The human evidence derives from academic clinical studies rather than pharmaceutical development programmes, and the mechanism is far better characterised than the practical use case.
Foundational work (2005-2011). Dhillo et al. (2005) showed kisspeptin-54 stimulates the HPG axis in men. George et al. (2011) gave intravenous kisspeptin-10 at 1 mcg/kg to healthy men and observed a rapid, dose-dependent LH rise from 4.1 IU/L to 12.4 IU/L within 30 minutes. Over a 22.5-hour infusion, LH increased from 5.4 to 20.8 IU/L and testosterone from 16.6 to 24.0 nmol/L (roughly 45%), with increased LH pulse frequency and pulse amplitude. Studied IV doses across the literature span 0.3 to 4 mcg/kg as bolus or infusion; 1 mcg/kg as a single bolus produced maximal LH stimulation.
Hypogonadal populations. George et al. (2013) found kisspeptin-10 increased LH pulse frequency, LH secretion, and serum testosterone in men with type 2 diabetes and mild biochemical hypogonadism, concluding kisspeptin agonists have a potential novel therapeutic role for enhancing endogenous testosterone secretion.
Sexual function. Comninos et al. (2023), a randomised, double-blind, crossover RCT in JAMA Network Open, enrolled 32 men with HSDD. Kisspeptin modulated activity in sexual processing regions, increased penile tumescence by up to 56% versus placebo, and increased behavioural measures of sexual desire. It was the first demonstration of effects on sexual brain processing in men with a diagnosed sexual disorder.
Tachyphylaxis. Jayasena et al. (2009): twice-daily kisspeptin-54 in women with hypothalamic amenorrhoea produced tachyphylaxis by 2 weeks; twice-weekly dosing maintained stimulation over 8 weeks.
Reviews and routes. Skorupskaite et al. (2024) in Endocrine Reviews described emerging therapeutic potential for kisspeptin and neurokinin B, with clinical development at an early stage. Sonmez et al. (2025) showed intranasal kisspeptin-54 rapidly stimulates gonadotropin release in healthy men and women without adverse events.
Gaps. No large-scale RCTs exist for subcutaneous kisspeptin-10 in otherwise healthy men with secondary hypogonadism, and no published dose-finding studies support the every-other-day subcutaneous protocol. Reported kinetics: post-subcutaneous peak LH at approximately 30 to 40 minutes, returning towards baseline by 180 minutes.
User reports
From public forums
There are fewer user reports for kisspeptin than for enclomiphene or HCG, and the reports are anecdotal, so they carry less weight than the studies above.
On the positive side, some users report better energy, libido, and mood within the first 2 to 3 weeks. People who have tried both kisspeptin and enclomiphene sometimes prefer kisspeptin because it does not block oestrogen, so it avoids the emotional flatness some feel on enclomiphene. Some describe feeling more natural on it than on other options. One forum user reported a 40% rise in total testosterone after one month on 100 mcg daily, but was taking other compounds at the same time, so that number cannot be pinned on kisspeptin alone.
On the negative side, the most common complaint is that the effect is too subtle. People expecting an HCG-sized jump are often disappointed. Some report no visible change on bloodwork. Injecting every other day is seen as a nuisance compared with HCG, and cost relative to effect comes up often.
In practice most users take 100 to 200 mcg under the skin every other day. Some take 100 mcg daily, and a smaller group doses twice a week. Most run 4 to 6 week cycles with blood tests. If you go in expecting a moderate, natural-feeling change rather than a dramatic one, you are more likely to be satisfied.
The anecdotal base for kisspeptin-10 is thinner than for enclomiphene or HCG, and none of it substitutes for controlled data.
Positive reports cluster around improved energy, libido, and mood within 2 to 3 weeks. Users with experience of both agents sometimes prefer kisspeptin to enclomiphene because it does not antagonise oestrogen receptors and therefore avoids the emotional flattening associated with SERMs. A subset describe the response as more physiological in character. One forum report of a 40% increase in total testosterone after one month on 100 mcg daily is confounded by concurrent compounds and cannot be attributed to kisspeptin.
Negative reports centre on subtlety. Users anticipating HCG-level testosterone increases frequently report disappointment; some report no discernible change on bloodwork. Every-other-day subcutaneous injection is considered burdensome relative to HCG's less frequent schedule, and cost relative to perceived effect is a recurring complaint.
Dosing patterns in practice: most users take 100 to 200 mcg subcutaneously every other day; some dose 100 mcg daily; a smaller group follows twice-weekly protocols. Most run 4 to 6 week cycles with lab checks. The satisfaction split maps cleanly onto expectation: those who understand that intact negative feedback caps the response tend to report satisfaction, those expecting axis-bypass pharmacology do not.
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
Kisspeptin works upstream, at the brain and pituitary. HCG works downstream, directly on the testicles. In theory they complement each other, and HCG can be added when kisspeptin alone does not produce enough of a response. The pair is also grouped for stronger luteinising hormone and follicle-stimulating hormone stimulation, and named Kisspeptin + PT-141 + HCG as a combination for sex drive, hormone balance, and fertility.
HCG is an LH-receptor agonist acting directly on Leydig cells; kisspeptin recruits the axis at the GnRH level. Theoretically complementary, and in secondary hypogonadism where upstream treatment alone is insufficient, HCG can be added to amplify the testicular response. Kisspeptin also increases HCG-stimulated progesterone secretion in luteal cells. No published data on the combination; both act on the HPG axis, so physician oversight is advised.
- Enclomiphene
Kisspeptin presses the accelerator on GnRH release. Enclomiphene releases the brake by stopping the brain from seeing oestrogen. Together they attack the same problem from two angles, but there is no published human research on the combination, so it is theory rather than evidence.
Kisspeptin provides direct KISS1R-mediated GnRH stimulation; enclomiphene removes oestrogenic negative feedback at the hypothalamus and pituitary via oestrogen receptor antagonism. Mechanistically additive, but no human data exist for the pairing, and a theoretical interaction is flagged since both influence the HPG axis.
No known interaction. Kisspeptin works on testosterone production; PT-141 works on a separate brain system that drives sexual desire. Kisspeptin + PT-141 + HCG is a known combination for sex drive, hormone balance, and fertility.
No known interaction; orthogonal systems. Kisspeptin acts on the HPG axis for testosterone production, PT-141 on the melanocortin system for arousal. The pairing addresses different problems and is part of the previously listed Kisspeptin + PT-141 + HCG libido and fertility stack.
No interaction concerns. Growth hormone peptides need to be taken fasted; kisspeptin does not, so there is no timing clash. It is commonly used for hormone support and fat loss alongside kisspeptin.
Different receptor systems and pathways, no interaction concerns. GH secretagogues require fasted administration; kisspeptin does not, so scheduling is unconstrained. Previously listed for synergistic hormone support and visceral fat reduction on the somatotropic axis.
A growth hormone peptide stack with no interaction concerns and no timing conflict with kisspeptin. It is commonly grouped with tesamorelin for hormone support and fat loss.
GH-axis secretagogues with no receptor overlap and no timing conflict. Grouped with tesamorelin for synergistic hormone support and fat loss alongside the gonadal axis.
Tissue repair and injury recovery, unrelated to the hormone effect.
Tissue repair and injury recovery, unrelated to the endocrine effect.
Grouped with BPC-157 for tissue repair and injury recovery.
Grouped with BPC-157 for tissue repair and injury recovery.
Amplifies the fat loss effect.
Amplifies lipolysis without glycaemic impact.
- Tirzepatide or Semaglutide
Suggested to improve insulin sensitivity and body composition.
GLP-1 based agents improving insulin sensitivity and body composition; kisspeptin itself increases insulin secretion, so glycaemic monitoring is sensible.
- Testosterone replacement therapy (TRT)
Not a sensible combination. TRT switches off the brain signals that kisspeptin is trying to stimulate, so adding kisspeptin is unlikely to do anything.
Pharmacologically incoherent. Exogenous testosterone and its oestradiol metabolite provide overwhelming negative feedback that silences GnRH neurons; KISS1R agonism is unlikely to overcome that suppression.
Common questions
How is kisspeptin different from enclomiphene?
Same goal, different route. Enclomiphene stops the brain from seeing oestrogen, which removes the brake on hormone production. Kisspeptin directly tells the brain to make more GnRH, pressing the accelerator. Enclomiphene has more human data. Kisspeptin works in a more natural way but has less evidence. Enclomiphene can cause emotional flatness in some people because it blocks oestrogen; kisspeptin blocks nothing.
Enclomiphene antagonises oestrogen receptors at the hypothalamus and pituitary, removing negative feedback on GnRH. Kisspeptin directly stimulates GnRH neurons via KISS1R. Enclomiphene has the larger human evidence base; kisspeptin has the more physiological mechanism and less clinical data. Enclomiphene can produce emotional flattening through central oestrogen blockade, which kisspeptin does not.
How is kisspeptin different from HCG?
HCG skips the brain and talks directly to the testicles. Kisspeptin works at the very top of the chain. HCG has decades of clinical data; kisspeptin is still emerging. HCG can push testosterone inside the testicles above natural levels; kisspeptin cannot, because the body's natural brake stays on.
HCG is an LH-receptor agonist acting directly on Leydig cells, bypassing hypothalamic and pituitary control. Kisspeptin acts at the top of the axis and preserves oestradiol negative feedback. HCG has decades of clinical data and can produce supraphysiological intratesticular testosterone; kisspeptin cannot because the feedback brake remains intact.
Will kisspeptin work for someone on TRT?
Probably not. TRT switches off the brain's hormone signals through negative feedback. Kisspeptin needs those signals to be switched on so it can boost them.
Probably not. Exogenous testosterone and its oestradiol metabolite suppress GnRH neurons through negative feedback. Kisspeptin requires functional GnRH neurons to stimulate, and those are largely silenced under TRT.
Does kisspeptin need to be cycled?
Taking it every day without breaks can make the receptors stop responding. Every-other-day or twice-weekly dosing helps prevent this. Some practitioners suggest 4 to 6 week cycles with breaks, though no published research has settled the best cycling pattern.
Continuous daily dosing risks KISS1R tachyphylaxis via beta-arrestin-mediated internalisation. Every-other-day or twice-weekly schedules mitigate this. Some practitioners recommend 4 to 6 week cycles with breaks; the optimal cycling protocol is not established in published research.
Can kisspeptin help with fertility?
In theory, yes. It raises both luteinising hormone and follicle-stimulating hormone, which support testosterone and sperm production together. That is an advantage over enclomiphene, which affects follicle-stimulating hormone less consistently. But no published human studies have tested kisspeptin-10 for fertility at the practical doses used.
In theory. Kisspeptin stimulates both LH and FSH, supporting Leydig cell testosterone production and Sertoli cell spermatogenesis simultaneously, an advantage over enclomiphene's less consistent FSH effect. No published human studies have evaluated kisspeptin-10 for fertility preservation or enhancement at practical subcutaneous doses.
How quickly does kisspeptin work?
Hormone changes are fast: luteinising hormone peaks around 30 to 40 minutes after an injection under the skin and drifts back towards baseline by about 3 hours. On every-other-day dosing, most people see changes on bloodwork within 2 to 4 weeks. Run baseline bloods before starting and recheck at 4 weeks.
Peak LH response occurs approximately 30 to 40 minutes after subcutaneous injection, returning towards baseline by 180 minutes. In the infusion study, testosterone rose from 16.6 to 24.0 nmol/L over 22.5 hours. On every-other-day protocols, bloodwork changes are typically seen within 2 to 4 weeks; baseline labs and a 4-week recheck are recommended.
Does kisspeptin have to be taken fasted?
Current guidance says no fasting is required, and it can be taken morning or evening. Earlier guidance on this site said fasting increased the response five to six fold. The two disagree; taking it fasted costs nothing and covers both.
Current guidance states no fasting is required and permits morning or evening dosing. Earlier guidance on this site cited a fasted LH response 5-6× the fed response. The two conflict; fasted administration is the conservative choice and carries no timing conflict with GH secretagogues.
References
- George JT, et al. Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men. Journal of Clinical Endocrinology and Metabolism. 2011;96(8):E1228-E1236.
- George JT, et al. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. European Journal of Endocrinology. 2013;169(2):229-236.
- Comninos AN, et al. Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial. JAMA Network Open. 2023;6(2):e2254313.
- Jayasena CN, et al. Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. Journal of Clinical Endocrinology and Metabolism. 2009;94(11):4315-4323.
- Skorupskaite K, et al. The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B. Endocrine Reviews. 2024;45(1):30-68.
- Thompson EL, et al. Chronic subcutaneous administration of kisspeptin-54 causes testicular degeneration in adult male rats. American Journal of Physiology: Endocrinology and Metabolism. 2006;291(5):E1074-E1082.
- Dhillo WS, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology and Metabolism. 2005;90(12):6609-6615.
- Sonmez K, et al. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. EBioMedicine. 2025.
This entry has been reviewed and expanded with additional reference material. Units are recomputed from the stated protocol.